SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain

Inclusion Criteria:

* Able to give written informed consent and willing to follow the study protocol.
* Age ≥ 16 years.
* Cytologically or histologically confirmed solid tumours of known primary site or multiple myeloma with painful bone metastases and poor control of bone pain in spite of pain medication including opioids
* WHO performance status ≤ 2
* Baseline BPI-SF score for pain on average ≥ 4 and ≤ 9 on a 0-10 numerical scale recorded on at least two separate days using the BPI-SF
* Adequate baseline haematological, hepatic and renal function, defined as follows:

  * Absolute neutrophil count ≥ 1.5 x 109/L
  * Haemoglobin \>9.0 g/dL (can be after transfusion)
  * Platelet count ≥ 100 x 109/L
  * Bilirubin ≤ 1.5 x ULN
  * ALT or AST ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases)
  * Creatinine ≤ 1.5 x ULN
* Ability to take and absorb oral medications.
* Female patients of childbearing potential (i.e. pre-menopausal females, females who have been menopausal for \< 1 year and not surgically sterilized) must provide a negative pregnancy test (serum) ≤ 7 days before study treatment begins and must agree to practice effective contraceptive measures (oral contraceptive pill, intrauterine device or diaphragm with spermicide) plus condoms during the study and for 30 days after last dose of saracatinib.
* Male patients with a partner of child-bearing potential (who is not using an acceptable highly effective method of contraception) or a pregnant partner must use effective contraceptive measures (see 8) plus condoms during the study and for 3 months after the last dose of saracatinib. Patients should abstain from sperm donation during the study and for 3 months after the last dose of saracatinib.

Exclusion Criteria:

* Life expectancy \< 3 months.
* Previous or planned radiotherapy at site of pain.
* Unstable cardiac disease in last 3 months.
* History of interstitial lung disease (bilateral, diffuse parenchymal lung disease) in view of known saracatinib-related pneumonitis.
* Unable to discontinue any medication with known moderate or potent inhibitory effect on CYP3A4, or or is a substrate of CYP3A4.
* Concomitant cytotoxic chemotherapy unless established on maintenance treatment for \> 6 weeks (not in a clinical trial).
* Unable to understand written or spoken English as the primary outcome is dependent on completion of the BPI-SF questionnaire.